Peptide Schedule
Follistatin-34417 residues (approx.)GNCWLRQAKNGRCQVLYEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Follistatin-344
Benefits
About Follistatin-344
Follistatin-344 is a naturally occurring glycoprotein that acts as a potent inhibitor of myostatin and activin — two TGF-beta superfamily members that put the brakes on muscle growth. When you inject FS-344, it's cleaved in vivo into two active forms: FS-315 (the circulating serum form) and FS-288 (which binds tightly to cell surfaces in muscle tissue). Both work by physically binding to myostatin and activin, preventing them from reaching their receptors on muscle cells. In animal studies, follistatin overexpression has produced some of the most dramatic muscle growth seen with any single intervention — mice showed 194-327% increases in muscle mass compared to controls. Gene therapy trials using AAV-delivered FS-344 in Becker muscular dystrophy patients showed measurable improvements in walking distance without serious adverse effects. It's worth noting that most impressive data comes from gene therapy delivery (continuous follistatin expression) rather than daily subcutaneous injection. The peptide form requires daily dosing because of its short ~90-minute half-life, and whether brief daily spikes produce the same degree of myostatin inhibition as continuous expression is an open question. There's also emerging research on follistatin's role in hair regrowth through Wnt/beta-catenin signaling and potential anti-fibrotic effects in liver tissue, though these applications are even more preliminary.
Who Should Consider Follistatin-344
- Individuals seeking muscle growth beyond natural limits
- Those experiencing age-related muscle loss (sarcopenia)
- Researchers studying TGF-beta signaling pathways
- Individuals interested in hair regrowth applications
How Follistatin-344 Works
Follistatin works by physically binding to and neutralizing members of the TGF-beta superfamily — primarily myostatin (GDF-8) and activin A. Myostatin signals through ActRIIB receptors to activate SMAD2/3 transcription factors, which suppress muscle protein synthesis and satellite cell activation. Follistatin acts as a molecular trap — it wraps around these ligands with high affinity and prevents them from reaching ActRIIB. FS-344 gets cleaved into FS-315 (circulates in serum with moderate heparin-binding affinity) and FS-288 (binds tightly to cell surface heparan sulfate proteoglycans, concentrating effects locally in tissue). Research in transgenic mice shows this inhibition results in both hypertrophy (larger fibers) and hyperplasia (more fibers) — a combination not typically seen with other anabolic agents.
What to Expect
Myostatin binding begins within hours. No visible changes yet.
Myostatin inhibition underway at molecular level. Possible increase in training recovery.
Increased muscle fullness and improved strength reported by users. First cycle ends — begin 4-week off period.
Cumulative gains across multiple cycles. Most noticeable muscle growth if combined with resistance training.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Daily |
| Moderate | 200mcg | Daily |
| Aggressive | 300mcg | Daily |
Note: Myostatin/activin inhibitor. FS-344 is cleaved in vivo to FS-315 (serum) and FS-288 (tissue-bound). Cycle 2 weeks on, 4 weeks off. Daily injection required due to short half-life. Use insulin syringe for accuracy at these low doses.
How to Inject Follistatin-344
Inject subcutaneously into the abdomen or thigh. Use an insulin syringe for accurate measurement at these low doses. Administer once daily, ideally at the same time each day. Rotate injection sites. Reconstitute gently — do not shake.
Cycling Protocol
Short cycles recommended due to limited long-term safety data. Some protocols extend to 4 weeks on.
Pharmacokinetics
Source: Estimated from PK modeling; FS-344 circulating half-life ~90 minutes
Loading the interactive decay curve.
Side Effects
Follistatin-344 doesn't have a well-established side effect profile in healthy humans using the injectable peptide form — that's the honest reality. Injection site reactions (redness, swelling, mild pain) are the most commonly reported issue. Gene therapy trials in muscular dystrophy patients showed good tolerability with no organ pathology, but those used a completely different delivery method. The bigger concern is what we don't know: myostatin exists for a reason, and chronically suppressing it could theoretically affect cardiac muscle, tendons, or ligament strength relative to rapidly growing skeletal muscle. No long-term safety studies exist for repeated subcutaneous FS-344 injection in healthy people.
Contraindications
- Active cancer or history of hormone-sensitive cancers
- Pregnancy or breastfeeding
- Cardiac conditions (theoretical risk from rapid muscle changes)
- Children and adolescents (growth plate concerns)
Drug Interactions
- Myostatin-targeting antibodies (additive effect, increased risk)
- TGF-beta pathway modulators (unpredictable interactions)
- Other anabolic agents including AAS and SARMs (compounded cardiovascular risk)
